Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Core Viewpoint - Xinhua Life Insurance Co., Ltd. reported a total original insurance premium income of 181.973 billion yuan from January 1, 2025, to October 31, 2025, representing a year-on-year growth of 17% [1] Summary by Category - **Company Performance** - The total original insurance premium income for Xinhua Insurance during the specified period is 181.973 billion yuan [1] - This figure indicates a year-on-year increase of 17% [1]

Group 1 - The core point of the article is that Xinhua Insurance (601336) reported a cumulative original insurance premium income of 181.973 billion yuan from January to October 2025, representing a year-on-year growth of 17% [1]

Core Insights - The insurance sector experienced a rise of 2.26% on November 12, with China Life Insurance leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Insurance Sector Performance - China Pacific Insurance (601318) closed at 60.03, up 1.40%, with a trading volume of 1.49 million shares and a transaction value of 8.99517 billion [1] - China Life Insurance (601628) closed at 44.60, up 1.99%, with a trading volume of 172,600 shares and a transaction value of 766 million [1] - China Property & Casualty Insurance (601601) closed at 36.50, up 2.56%, with a trading volume of 485,400 shares and a transaction value of 1.763 billion [1] - New China Life Insurance (601336) closed at 69.48, up 3.56%, with a trading volume of 273,500 shares and a transaction value of 1.887 billion [1] - China Reinsurance (601319) closed at 8.82, up 4.01%, with a trading volume of 1.2669 million shares and a transaction value of 1.107 billion [1] Capital Flow Analysis - The insurance sector saw a net inflow of 495 million from institutional investors, while retail investors experienced a net outflow of 669 million [1] - China Life Insurance (601318) had a net inflow of 27.3 million from institutional investors, while retail investors had a net outflow of 357 million [2] - New China Life Insurance (601336) had a net inflow of 13.1 million from institutional investors, with a net outflow of 15 million from retail investors [2] - China Property & Casualty Insurance (601601) experienced a net outflow of 7.24 million from institutional investors and a net outflow of 1.46 million from retail investors [2] - China Reinsurance (601319) had a net inflow of 7.018 million from institutional investors, but retail investors had a significant net outflow of 64.42 million [2]

Core Viewpoint - Xinhua Insurance (01336.HK) reported a cumulative original insurance premium income of RMB 181.973 billion from January 1 to October 31, 2025, representing a year-on-year growth of 17% [1] Group 1 - The company is committed to a customer-centric strategy, continuously improving its "insurance + service + investment" collaborative model for high-quality and sustainable development [1] - The company is focusing on multi-dimensional efforts in product, channel, team, ecosystem, operation, and technology to deepen systematic, professional, and market-oriented reforms [1] - The goal is to achieve dual enhancements in scale and value, as well as dual optimization in quality and structure for high-quality development [1]

公司深入践行"以客户为中心"的战略导向，持续完善"保险+服务+投资" 三端协同的高质量、可持续发展模式，从产品、渠道、队伍、生态、运营、科技 等多维度同步发力，深化体系化、专业化、市场化改革，致力于公司规模价值双 提升、品质结构双优化的高质量发展。 上述累计原保险保费收入数据未经审计，提请投资者注意。 | A股证券代码：601336 | A股证券简称：新华保险 编号：2025-061号 | | --- | --- | | H股证券代码： 01336 | H股证券简称：新华保险 | 新华人寿保险股份有限公司 保费收入公告 新华人寿保险股份有限公司董事会及全体董事保证本公告内容不存 在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 根据中华人民共和国财政部《企业会计准则第 25 号——原保险合同》（财 会〔2006〕3 号）及《保险合同相关会计处理规定》（财会〔2009〕15 号），新华 人寿保险股份有限公司（以下简称"公司"）于 2025 年 1 月 1 日至 2025 年 10 月 31 日期间累计原保险保费收入为人民币 18,197,302 万元，同比增长 17%。 ...

智通财经APP讯，新华保险(01336)公布，该公司于 2025 年 1 月 1 日至 2025 年 10 月 31 日期间累计原保 险保费收入为约人民币1819.73亿元，同比增长 17%。 ...

Core Viewpoint - The company, Xinhua Insurance, reported a cumulative original insurance premium income of approximately RMB 181.973 billion from January 1, 2025, to October 31, 2025, representing a year-on-year growth of 17% [1] Group 1 - The cumulative original insurance premium income for the specified period is approximately RMB 181.973 billion [1] - The year-on-year growth rate of the insurance premium income is 17% [1]

Core Viewpoint - Xinhua Insurance reported a cumulative original insurance premium income of 181.973 billion yuan for the period from January to October 2025, representing a year-on-year growth of 17% [1] Company Summary - The cumulative original insurance premium income for Xinhua Insurance from January to October 2025 is 181.973 billion yuan [1] - The year-on-year growth rate of the original insurance premium income is 17% [1]

Core Viewpoint - Xinhua Insurance (601336.SH) reported a total original insurance premium income of RMB 181.973 billion from January 1, 2025, to October 31, 2025, representing a year-on-year growth of 17% [1] Group 1 - The total original insurance premium income for the specified period is RMB 181.973 billion [1] - The year-on-year growth rate of the insurance premium income is 17% [1]